Purchase this article with an account.
Izabela N. Frota de Almeida, Luciana N. Frota de Almeida, Edmundo Frota de Almeida Sobrinho, Givago S. Souza, Bruno D. Gomes, Alexandre M. Rosa, Luiz Carlos L. Silveira; Electroretinography And Optical Coherence Tomography In Patients With Age Related Macular Degeneration Before, During, And After Treatment With Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6071.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate retinal morphology and electrophysiology of patients with choroidal neovascular membrane (CNV), secondary to age-related macular degeneration (AMD), before, during, and after treatment with ranibizumab.
Sixteen patients, 71.2 ± 9.9 years old, diagnosed with CNV secondary to AMD in one or both eyes were studied with optical coherence tomography (Stratus OCT), multifocal (mfERG-103 hexagons protocol) and full field electroretinography (ffERG; scotopic and photopic protocols) (VERIS). Intravitreal injections of 0.05 ml anti-angiogenic ranibizumab were administered at 1 month intervals between each injection over a 3 month period. OCT, mfERG, and ffERG were performed before the first injection (D0) and at 1, 2, and 3 months after each injection (D30, D60, and D90).
Twenty-two eyes were tested. Visual acuity was 1.64 ± 0.72 logMAR. OCT performed before treatment showed increased thickness of retinal inner layers in the macula due to intraretinal fluid and increased thickness of the retinal pigment epithelium-choriocapillaris complex (RPE-CC) related to CNV. Follow-up OCT examination showed reduction of intraretinal oedema but persistence of RPE-CC complex increased thickness, forming a subretinal scar in the fovea and inner macula (p < 0.05, ANOVA one way, Tukey test). mfERG amplitude response had not recovered at the macula after treatment. ffERG photopic amplitude and implicit time had no statistical difference after the treatment, but scotopic ERG b-wave implicit time was longer after the treatment than before (p < 0.05).
The results suggest that ranibizumab decreases retinal oedema as observed by OCT, but it does not seem to recovery retinal function as evaluated by the mfERG and ffERG.
This PDF is available to Subscribers Only